Tarek Zeidan

Tarek Zeidan is the Vice President of Pharmaceutical Sciences. He holds a Ph.D. in organic chemistry from Florida State University, where he studied the kinetics of enediyne cyclization and investigated the mechanism for photochemical cycloaddition reactions between dienes and acetylenes. He completed a postdoctoral fellowship at Northwestern University, focusing on the dynamics of photoinduced charge separation in short DNA hairpins. Zeidan received his B.S. in chemistry from the American University of Beirut. He began his career at Alkermes Inc., developing long-acting injectables and co-inventing the LinkeRx® technology platform, which uses prodrugs to deliver medicine over several weeks. He oversaw technical and CMC activities for several programs, including Aristada® and Aristada Initio®, and served as the Technical Team Lead for ALKS 4230 (nemvaleukin alpha), an engineered fusion protein for treating mucosal melanoma and platinum-resistant ovarian cancer. Zeidan has worked in various R&D functions at Alkermes, including pre-formulation, formulation development, and analytical development. He was also the Head of the Analytical R&D group at Lyndra Therapeutics, working on the LYNXTM technology to deliver long-acting oral therapies. He led the analytical activities for LYN-005, an investigational program designed to deliver the antipsychotic drug risperidone as a single weekly oral capsule. Zeidan has more than 50 cumulative peer-reviewed publications, patents, and presentations. He is recognized as a people-oriented leader with a passion for mentorship and coaching, striving to build a culture of trust, transparency, and inclusion.